Molecule News and Research

RSS

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Impel NeuroPharma, a medical device company whose technology is designed to enable pharmaceutical drugs to bypass the blood-brain barrier and enter the central nervous system (CNS), today announced that it was selected to receive a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense's Chemical and Biological Defense SBIR Program entitled, "Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents."

24 Jun 2011

Protein globin E helps avian eyes 'breathe' and contributes to visual acuity

Say what you will about bird brains, but our feathered friends sure have us -- and all the other animals on the planet -- beat in the vision department, and that has a bit to do with how their brains develop.

24 Jun 2011

Discovery sheds new light on initiation of vision process

A discovery by a team of researchers led by a Syracuse University physicist sheds new light on how the vision process is initiated. For almost 50 years, scientists have believed that light signals could not be initiated unless special light-receptor molecules in the retinal cells first changed their shape in a process called isomerization.

24 Jun 2011

Small 'antifreeze' molecules more effective in protecting proteins than larger ones

Scientists have made an important step forward in their understanding of cryoprotectants - compounds that act as natural 'antifreeze' to protect drugs, food and tissues stored at sub-zero temperatures.

24 Jun 2011

Researchers identify novel viral sensor complex

Double-stranded (ds) RNA viruses are a diverse group of viruses that include rotaviruses, a common cause of gastroenteritis. The ability of the immune system to detect and destroy viruses is critical for human health and survival.

24 Jun 2011

New research helps explain how memories are stored at synapses

Have a tough time remembering where you put your keys, learning a new language or recalling names at a cocktail party? New research from the Lisman Laboratory at Brandeis University points to a molecule that is central to the process by which memories are stored in the brain. A paper published in the June 22 issue of the Journal of Neuroscience describes the new findings.

24 Jun 2011

Copenhagen chemist reveals mechanism behind deadly infections

Anthrax, septicemia and meningitis are some of the planet's most deadly infections. In part because doctors lack basic insights to prevent and cure diseases caused by so called Gram-positive bacteria. Now, a chemist from the University of Copenhagen has revealed the mechanism behind these deadly infections.

24 Jun 2011

Researchers discover new mechanism for origin of Barrett's esophagus

Researchers have discovered a new mechanism for the origin of Barrett's esophagus, an intestine-like growth in the esophagus that is triggered by chronic acid reflux and often progresses to esophageal cancer.

24 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Molecularly targeted glue for cancer

"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."

23 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

Reginald C. Farrow and Zafer Iqbal, research professors at NJIT, were awarded a patent today for an improved method of fabricating arrays of nanoscale electrical probes. Their discovery may lead to improved diagnostic tools for measuring the spatial variation of electrical activity inside biological cells.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

Novel method of disguising nanoparticles as red blood cells to fight cancer

Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, which will enable them to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. Their research was published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

22 Jun 2011

Palatin receives U.S. patent titled ‘Amino Acid Surrogates for Peptidic Constructs'

Palatin Technologies, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs."

22 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury

Ischemix today announced positive top line data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury.

17 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011